戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 dy fluids (e.g., semen and saliva, semen and vaginal secretions).
2 cipants had detectable ZIKV RNA in saliva or vaginal secretions.
3 ncluding potassium hydroxide preparation) of vaginal secretions.
4 retes putrescine that is readily detected in vaginal secretions.
5 ical Amsel criteria and direct Gram stain of vaginal secretions.
6 emonstrated by high levels of IgA in eye and vaginal secretions.
7 cific antibody responses in the serum and in vaginal secretions.
8  a significant effect on HIV-1 RNA levels in vaginal secretions.
9 ed Th2-MoPn produced higher levels of IgA in vaginal secretions.
10 gnant women for trichomoniasis by culture of vaginal secretions.
11 ell-free virus from matched blood plasma and vaginal secretions.
12 ificantly reduced the amount of HIV-1 RNA in vaginal secretions.
13 erline levels of mucosal Abs determined from vaginal secretions.
14  specific IgA antibody activity in serum and vaginal secretions.
15  of Env-specific IgG antibodies in serum and vaginal secretions.
16 ld induce an antibody response detectable in vaginal secretions.
17 ti-PspA immunoglobulin G titers in serum and vaginal secretions.
18 culture of Trichomonas vaginalis from pooled vaginal secretions.
19 al fluid (CSF) and semen, but transiently in vaginal secretions.
20 esting transepithelial transport of IgA into vaginal secretions.
21 c IgG and IgA responses in serum, feces, and vaginal secretions.
22 that cellular replication of HIV-1 occurs in vaginal secretions and can result in a virus population
23       Furthermore, anti-gp160 IgG and IgA in vaginal secretions and fecal extracts were induced after
24 tant sites, including mucosal IgA in saliva, vaginal secretions and feces, and IgG in blood.
25 immunization in inducing SIV-specific IgA in vaginal secretions and generated greater IgA responses i
26 late with Env-specific antibody responses in vaginal secretions and protection against infection.
27  and SIV-specific IgGs were also observed in vaginal secretions and saliva.
28 r ratios and specific antibody activities in vaginal secretions and serum indicated that IgG viral an
29 ncreased glycoprotein-specific IgG titers in vaginal secretions and serum to comparable levels in Iva
30       Maternal sources (colostrum, feces and vaginal secretion) and newborn fecal samples were analyz
31 s type 1 (HIV-1) RNA levels in blood plasma, vaginal secretions, and cervical mucus of 52 HIV-1-infec
32 ant biological fluids--blood, semen, saliva, vaginal secretions, and menstrual blood--in an attempt t
33 was produced in the vagina and released into vaginal secretions at 6 weeks and 10 months after vagina
34                                              Vaginal secretions contain chemokines that drive neutrop
35 d had yeast identified on wet preparation of vaginal secretions during the past 60 days (aOR, 4.06 [9
36 s to the model vaccine antigens in serum and vaginal secretions following IN and SL application.
37 ecal microbiota was similar to colostrum and vaginal secretion from day 1 up to 7.
38                                 Cervical and vaginal secretions from 17 women infected with human imm
39                                 Cervical and vaginal secretions from 318 women were evaluated for the
40                               In this study, vaginal secretions from HIV-1-infected women were examin
41                     Additionally, removal of vaginal secretions from immune mice 10 min before vagina
42 atinocyte-derived chemokine were elevated in vaginal secretions from infected BALB/c mice, but not in
43                                     Sera and vaginal secretions from infected mice were analyzed for
44 ta, maternal and cord blood, breastmilk, and vaginal secretions from people who had recovered from Eb
45 624 participants and obtained 423 samples of vaginal secretions from them, including 193 HPV-negative
46      Fetal fibronectin (fFN) in cervical and vaginal secretions has been used as a predictor of prete
47 tibodies to HGH were detectable in serum and vaginal secretions in rats immunized with pCMV/HGH.
48 pport the hypothesis that sexual exchange of vaginal secretions is a possible mechanism for acquisiti
49 ding of HIV-1 infected cells in cervical and vaginal secretions may be important determinants of sexu
50 The increase of proinflammatory cytokines in vaginal secretions may serve as a surrogate marker of un
51 correlates of HIV-1 shedding in cervical and vaginal secretions, most notably hormonal contraceptive
52 , significantly less IgG was detected in the vaginal secretions of B7KO mice than in those from wild-
53 vely, the data indicate that IgG antibody in vaginal secretions of immune mice provides early protect
54 t that antibodies are not readily present in vaginal secretions of infected mice and thus have a limi
55 ulin A (IgA) antibody activity in saliva and vaginal secretions of mice given AgI/II with LT-IIa or L
56 tigated the protective role of antibodies in vaginal secretions of mice that were immune to vaginal c
57                                              Vaginal secretions of p.o.-immunized animals neutralize
58    Large numbers of chlamydiae were found in vaginal secretions of progesterone-treated and combinati
59 hough the viral antibody titers in serum and vaginal secretions of recipient mice at the time of chal
60 3.12 vs. 3.00 log(10) copies/swab, P=1.0) in vaginal secretions of women receiving vitamin A, compare
61  has been reported in the amniotic fluid and vaginal secretions of women who deliver preterm.
62 he detection of proviral DNA in cervical and vaginal secretions (P<.001 and P = .030, respectively).
63 m the LH surge and the level of HIV-1 RNA in vaginal secretions (P=.4).
64 rual cycles in 25 women, HIV-1 RNA levels in vaginal secretions ranged from <1000 to 5.3x10(7) copies
65                                              Vaginal secretion/serum titer ratios and specific antibo
66 IgG plasma cells in the vagina and increased vaginal secretion/serum titer ratios to 3.0- to 4.7-fold
67  in blood plasma was correlated with that in vaginal secretions (Spearman's rank correlation coeffici
68                     In both blood plasma and vaginal secretions, the amounts of cell-free and cell-as
69 , as was the median HIV-1 DNA copy number in vaginal secretions (undetectable versus 1.0 HIV-1 DNA co
70 mmunodeficiency virus (HIV) type 1 levels in vaginal secretions, vaginal lavage samples were collecte
71  products from cell-free viral RNA in paired vaginal secretion (VS) and blood plasma (BP) samples of
72  type 1 (HIV-1) RNA shedding in cervical and vaginal secretions was examined daily for 17 HIV-1-serop
73 e collected serum, urine, saliva, semen, and vaginal secretions weekly for the first month and then a
74            However the highest IgA titres in vaginal secretions were achieved after IN immunisations
75      Concentrations of VRC01-N and HSV8-N in vaginal secretions were assessed over time to generate p
76 ll-free HIV-1 RNA levels in blood plasma and vaginal secretions were negatively correlated with CD4+
77 ions and ex vivo bioactivity of both mAbs in vaginal secretions were significantly elevated and thus
78 ore pronounced immune response in saliva and vaginal secretion, while rectal immunization was more po
79 preparation hypothesis posits that increased vaginal secretion would lubricate and protect the vagina